What is MENS's relative strength rating?

MENS ranks at the 25th percentile over 1 month, 55th percentile over 3 months, 25th percentile over 6 months, 3th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.

What sector is MENS in?

MENS is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.

Is MENS in a leading sector?

Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). MENS benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.

How volatile is MENS?

MENS currently shows a 20-day average daily range (ADR%) of 8.6%, a 90-day beta versus the S&P 500 of 0.97. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.

Does MENS have a seasonal pattern?

TickerStance computes MENS's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what MENS has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

When did MENS last report earnings?

No SEC EDGAR filings are linked to MENS in the current TickerStance fundamentals database. This can occur for tickers without a matched CIK (some ADRs, ETFs, and recently listed securities) or when the fundamentals pipeline has not yet processed this ticker.

Jyong Biotech Ltd. Ordinary Shares (MENS) · RS 25

TODAY'S READ · AS OF 2026-08-24

As of 2026-08-24, Jyong Biotech Ltd. Ordinary Shares (MENS) has a 3-month relative strength percentile of 55 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 35. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.6%, relative volume 0.45×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.

RS methodology →

Market-wide RS; lit = leaderboard

Lenses lit

3 month55pctile

6 month25pctile

1 year3pctile

Classic10IBD pctile

LDR2leadership

0 of 5 lenses lit · avg RS pctile 19

✓ADR%8.6%✓A/DB!RVOL0.45×!$ Vol$174K

Market backdrop

47.8Neutral

Trend30% weight44.9 Breadth30% weight50.6 Leadership20% weight42.4 Macro20% weight59.0 Full stance breakdown →

§ Seasonality

10y · since 2025

Best monthAug on averageavg +187.57% · 100% win · n 1

Worst monthDec on averageavg -85.48% · 0% win · n 1

MENS monthly seasonality strip
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
1	MENS Jan avg: -40.25% median: -40.25% win: 0% σ: 0.00% n: 1 2025-06-18 → 2026-07-31	MENS Feb avg: -9.32% median: -9.32% win: 0% σ: 0.00% n: 1 2025-06-18 → 2026-07-31	MENS Mar avg: 0.47% median: 0.47% win: 100% σ: 0.00% n: 1 2025-06-18 → 2026-07-31	MENS Apr avg: 5.58% median: 5.58% win: 100% σ: 0.00% n: 1 2025-06-18 → 2026-07-31	MENS May avg: -3.08% median: -3.08% win: 0% σ: 0.00% n: 1 2025-06-18 → 2026-07-31	MENS Jun avg: -10.92% median: -10.92% win: 0% σ: 7.08% n: 2 2025-06-18 → 2026-07-31	MENS Jul avg: 64.05% median: 64.05% win: 100% σ: 85.11% n: 2 2025-06-18 → 2026-07-31	MENS Aug avg: 187.57% median: 187.57% win: 100% σ: 0.00% n: 1 2025-06-18 → 2026-07-31 (current)	MENS Sep avg: -28.15% median: -28.15% win: 0% σ: 0.00% n: 1 2025-06-18 → 2026-07-31	MENS Oct avg: 13.66% median: 13.66% win: 100% σ: 0.00% n: 1 2025-06-18 → 2026-07-31	MENS Nov avg: -39.23% median: -39.23% win: 0% σ: 0.00% n: 1 2025-06-18 → 2026-07-31	MENS Dec avg: -85.48% median: -85.48% win: 0% σ: 0.00% n: 1 2025-06-18 → 2026-07-31

Evidence · 1 of 3

Receipts behind the read

0 of 5 pass

Leadership

Is it leading?

Relative strength across horizons plus the leadership score.

1m

25

3m

55

6m

25

1y

3

LDR

—

StageWeinstein stage analysis

Stage 1 · Basing

Smart money

Who's accumulating?

Accumulation rating, relative volume, U/D ratio, breakout-day proof.

Fundamentals · MENS

Does the business back the chart?

No SEC filings on file for this ticker. Fundamentals section requires EDGAR coverage.

Evidence · 2 of 3

Sector context

Healthcare · 82th pctile in sector

Top peers · Healthcare

Who else is leading?

ELOX
99RS 3m
FBRX
99RS 3m
MRNA
99RS 3m
MENS
55RS 3m · you

Sector vs market

Healthcare · 3 of 11

Energy100

Technology91

Healthcare82

Financials

PEERS · Pharmaceutical Products

Same industry, closest relative strength

4 peers · by RS6M

UNCYUnicycive Therapeutics, Inc. Common Stock25 INTSIntensity Therapeutics, Inc. Common stock25 AZNAstraZeneca PLC25 CRVSCorvus Pharmaceuticals, Inc.26

ETF OWNERS

ETFs holding MENS

MENS appears in 1 ETF as of May 2026: IBBQ at 0.01% weight, $9K notional.

Held by 1 ETFs · $9K across latest filings · largest weight 0.01% (IBBQ).

ETFs holding: 1
Total value: $9K
Top 3 concentration: 100.0%
Max weight: IBBQ · 0.01%

Top 1 by value, from SEC N-PORT-P filings dated May 2026.

ETFs holding MENS ranked by value
ETF	Weight	Value	Δ
IBBQ	0.01%	$9K	—

As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.

Public attention · MENS

Is the crowd watching?

54/ 100 · vs its own 90-day norm▼ 4 vs 7dOverlooked

Weak relative strength and quiet attention. Little to read here either way.

Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.

News

Jyong (MENS) Move: Gains 2.88% to Reach $2.14 on the Day; Current Setup: the Session Ends Within the Reported Technical Boundaries on the Day - Volume Nodes - vinanet.vn · vinanet.vn

Company snapshot

SectorHealthcare

IndustryPharmaceutical Products

SIC2834

Float31.1Mshares

Shares out74.2Mshares

Market cap$164.8MMicro Cap

FAQ

Frequently asked questions

What is MENS's relative strength rating?: MENS ranks at the 25th percentile over 1 month, 55th percentile over 3 months, 25th percentile over 6 months, 3th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
What sector is MENS in?: MENS is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data. Healthcare is currently ranked 3 of 11 sectors by relative strength.
Is MENS in a leading sector?: Yes — Healthcare ranks at the 82th percentile by sector relative strength, placing it in the leading band (≥ 70th percentile). MENS benefits from positive sector-level momentum, which historically correlates with above-average stock-level RS performance in the O'Neil / Minervini framework.
How volatile is MENS?: MENS currently shows a 20-day average daily range (ADR%) of 8.6%, a 90-day beta versus the S&P 500 of 0.97. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
Does MENS have a seasonal pattern?: TickerStance computes MENS's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what MENS has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.

Jyong Biotech Ltd. Ordinary Shares (MENS) — Stance & relative strength

Lenses lit

Market backdrop

§ Seasonality

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

ETFs holding MENS

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?

§ Seasonality

Jyong Biotech Ltd. Ordinary Shares (MENS) — Stance & relative strength

MENS is not confirmed as a leader. 55 is not yet a leadership-grade RS read, Market Stance is 47.8

Lenses lit

Market backdrop

Receipts behind the read

Is it leading?

Who's accumulating?

Does the business back the chart?

Sector context

Who else is leading?

Healthcare · 3 of 11

Same industry, closest relative strength

ETFs holding MENS

Is the crowd watching?

Company snapshot

Frequently asked questions

How much does it move?